ATE478058T3 - 3,7-diamino-10h-phenothiazinsalze und ihre verwendung - Google Patents

3,7-diamino-10h-phenothiazinsalze und ihre verwendung Download PDF

Info

Publication number
ATE478058T3
ATE478058T3 AT07732164T AT07732164T ATE478058T3 AT E478058 T3 ATE478058 T3 AT E478058T3 AT 07732164 T AT07732164 T AT 07732164T AT 07732164 T AT07732164 T AT 07732164T AT E478058 T3 ATE478058 T3 AT E478058T3
Authority
AT
Austria
Prior art keywords
4alkyl
4alkenyl
halogenated
independently selected
diamino
Prior art date
Application number
AT07732164T
Other languages
English (en)
Inventor
Claude Wischik
Janet Rickard
Charles Harrington
David Horsley
John Storey
Colin Marshall
James Sinclair
Thomas Baddeley
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38421429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE478058(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of ATE478058T3 publication Critical patent/ATE478058T3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B21/00—Thiazine dyes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
AT07732164T 2006-03-29 2007-03-28 3,7-diamino-10h-phenothiazinsalze und ihre verwendung ATE478058T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78669006P 2006-03-29 2006-03-29
PCT/GB2007/001103 WO2007110627A2 (en) 2006-03-29 2007-03-28 3,7-diamino-10h-phenothiazine salts and their use

Publications (1)

Publication Number Publication Date
ATE478058T3 true ATE478058T3 (de) 2010-09-15

Family

ID=38421429

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07732164T ATE478058T3 (de) 2006-03-29 2007-03-28 3,7-diamino-10h-phenothiazinsalze und ihre verwendung

Country Status (18)

Country Link
US (5) US7888350B2 (de)
EP (1) EP2013191B3 (de)
JP (3) JP5520043B2 (de)
KR (1) KR100983301B1 (de)
CN (5) CN101460472B (de)
AT (1) ATE478058T3 (de)
AU (1) AU2007231124B2 (de)
CA (1) CA2646163C (de)
DE (1) DE602007008550D1 (de)
DK (1) DK2013191T6 (de)
EA (1) EA014552B1 (de)
ES (1) ES2349322T7 (de)
HR (1) HRP20100614T4 (de)
IL (2) IL194516A (de)
MY (1) MY143757A (de)
PL (1) PL2013191T6 (de)
PT (1) PT2013191E (de)
WO (1) WO2007110627A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5186212B2 (ja) 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
KR100983301B1 (ko) 2006-03-29 2010-09-20 위스타 레보레이토리스 리미티드 ３,７―다이아미노―１０ｈ―페노티아진염 및 이의 용도
PL2004155T3 (pl) 2006-03-29 2018-08-31 Wista Laboratories Ltd. Inhibitory agregacji białek
AU2007274057B2 (en) 2006-07-11 2012-12-13 TauRx Therapeutics Management Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
CA2686513C (en) * 2007-04-03 2017-06-13 Prosetta Bioconformatics Inc. Diamino-benzothiazine derivatives as antiviral agents
PL2167095T3 (pl) * 2007-06-19 2019-11-29 Wista Lab Ltd Związki fenotiazynowe do leczenia łagodnych zaburzeń poznawczych
FR2920775B1 (fr) 2007-09-07 2009-11-06 Pharma Hydro Dev P H D Soc Par Nouveaux composes diaminophenothiazine, leur procede de preparation et leurs utilisations.
EP2954932B1 (de) 2007-10-03 2018-09-19 WisTa Laboratories Ltd. Therapeutische verwendung von diaminophenothiazinen
PT3112358T (pt) 2008-12-10 2020-06-23 Wista Lab Ltd Sais de xantílio 3,6-dissubstituídos
MX2012003035A (es) 2009-09-24 2012-06-12 Wista Lab Ltd Proceso.
BR112012006638B1 (pt) * 2009-09-24 2020-05-26 Wista Laboratories Ltd. Forma c de di-hidrato de cloreto de metiltionínio, seu processo de preparação, e composição farmacêutica
WO2011137447A1 (en) 2010-04-30 2011-11-03 Prostetta Antiviral Inc. Antiviral compounds
SG10201602111VA (en) 2010-11-30 2016-04-28 Wista Lab Ltd Formulations Comprising Methylthioninium Chloride
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
JP5898701B2 (ja) 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
WO2012145567A1 (en) 2011-04-20 2012-10-26 Prosetta Antiviral Inc. Antiviral compounds
US20130315825A1 (en) * 2012-05-03 2013-11-28 Washington University Tricyclic heteroaromatic compounds as alpha-synuclein ligands
GB201512678D0 (en) * 2015-07-20 2015-08-26 Wista Lab Ltd Methods of chemical synthesis
CN105541756B (zh) * 2015-12-17 2018-02-09 陕西方舟制药有限公司 一种制备1‑(3，7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法
ITUA20163526A1 (it) 2016-05-17 2017-11-17 Icrom Spa Procedimento per la preparazione di composti diamminofenotiazinici ad elevato grado di purezza
CN109789148A (zh) * 2016-07-25 2019-05-21 维斯塔实验室有限公司 二氨基吩噻嗪的给药和剂量
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
GB201621817D0 (en) * 2016-12-21 2017-02-01 Wista Lab Ltd Methods of chemical synthesis
CN107253936B (zh) * 2017-06-23 2021-07-23 复旦大学 一类可用于次氯酸检测的荧光探针及其制备方法和应用
CN108129418A (zh) * 2017-12-22 2018-06-08 郑州大学 吩噻嗪-氨基二硫代甲酸酯衍生物及其制备方法和应用
ES2989458T3 (es) 2018-07-26 2024-11-26 Wista Lab Ltd Dosis optimizada de diaminofenotiazinas en poblaciones
AU2018440060B2 (en) 2018-09-05 2025-04-10 Genting Taurx Diagnostic Centre Sdn Bhd Network methods for neurodegenerative diseases
CN109223800A (zh) * 2018-10-26 2019-01-18 辽宁大学 3,7-二对甲苯胺基-吩噻嗪-5-鎓碘化物与超声协同在抑制肿瘤细胞增殖中的应用
JP7748876B2 (ja) 2019-04-05 2025-10-03 タウク３ バイオロジクス リミテッド 抗タウｃ３抗体及びその使用
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
EP4146225B1 (de) * 2020-05-05 2024-10-09 WisTa Laboratories Ltd. Methylthioninium-verbindungen zur verwendung bei der behandlung von hypoxämie
GB202006659D0 (en) 2020-05-05 2020-06-17 Wista Lab Ltd Therapeutic treatments
EP4146223A1 (de) 2020-05-05 2023-03-15 WisTa Laboratories Ltd. Methylthioninium-verbindungen zur verwendung bei der behandlung von covid-19
GB202010652D0 (en) 2020-07-10 2020-08-26 Wista Lab Ltd Anti-tau antibodies
DE102020212508A1 (de) * 2020-10-02 2022-04-07 Continental Reifen Deutschland Gmbh Verbindung, Kautschukmischung enthaltend die Verbindung, Fahrzeugreifen, der die Kautschukmischung in wenigstens einem Bauteil aufweist, Verfahren zur Herstellung der Verbindung sowie Verwendung der Verbindung als Alterungsschutzmittel und/oder Antioxidationsmittel und/oder Antiozonant und/oder Farbstoff
GB202204185D0 (en) 2022-03-24 2022-05-11 Wista Lab Ltd Oral treatment
AU2023279800A1 (en) 2022-05-31 2024-12-19 TauRx Therapeutics Management Ltd Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
WO2024061971A1 (en) 2022-09-21 2024-03-28 Wista Laboratories Ltd. Novel formulations and vehicles
US12410394B2 (en) 2023-01-06 2025-09-09 Athergen, Inc. Composition comprising nicotinamide mononucleotide and leucomethylene blue
WO2024184146A1 (en) 2023-03-03 2024-09-12 Wista Laboratories Ltd. Diaminophenothiazine for the treatment of microvascular brain disease disease
CN117447421A (zh) * 2023-10-30 2024-01-26 上海沃凯生物技术有限公司 一种3,7-双-（二甲胺基）-吩噻嗪的合成方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE569430A (de) * 1957-07-17
US3641016A (en) * 1968-02-16 1972-02-08 Egyt Gyogyszervegyeszeti Gyar Thionine derivatives
JPS52105931A (en) * 1976-03-02 1977-09-06 Mita Industrial Co Ltd New leuco coloring matters and process for manufacture thereof
US4309255A (en) 1980-09-10 1982-01-05 International Business Machines Corporation Electrochromic recording paper
US4622395A (en) * 1984-10-01 1986-11-11 Minnesota Mining And Manufacturing Company Phenoxazine and phenothiazine dyes and leuco forms thereof
US4647525A (en) * 1984-10-01 1987-03-03 Minnesota Mining And Manufacturing Company Stabilized leuco phenazine dyes and their use in an imaging system
GB8724412D0 (en) 1987-10-19 1987-11-25 Medical Res Council Protein
US5571666A (en) * 1988-10-28 1996-11-05 Oklahoma Medical Research Foundation Thiazine dyes used to inactivate HIV in biological fluids
CA2011116C (en) * 1989-03-06 1999-11-16 Murray A. Kaplan Lyophilized bmy-28142 dihydrochloride for parenteral use
US5220009A (en) * 1990-05-03 1993-06-15 Yeda Research And Development Company Limited Phenothiazinium salts and their use for disinfecting aqueous effluents
JPH0725786A (ja) 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
AU2414092A (en) 1991-08-01 1993-03-02 Paul H. Voorheis Diagnostic method for alzheimer's disease
WO1993003177A1 (en) 1991-08-09 1993-02-18 Massachusetts Institute Of Technology Novel tau/neurofilament protein kinases
DE4140192C2 (de) 1991-12-05 1996-02-29 Alfatec Pharma Gmbh Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen
DE69233767D1 (de) 1991-12-06 2009-09-17 Max Planck Gesellschaft Verwendung von Protein-Kinasen zur Diagnose und Behandlung der Alzheimer-Krankheit
JPH06289015A (ja) 1993-03-30 1994-10-18 Sunstar Inc フェノチアジン系色源体安定化組成物
GB9316727D0 (en) 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
GB9317193D0 (en) 1993-08-18 1993-10-06 Zeneca Ltd Method
WO1996004915A1 (en) 1994-08-08 1996-02-22 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
DE4430091A1 (de) 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5804601A (en) 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
US5693638A (en) * 1996-02-23 1997-12-02 Myers; Daniel Method of treating a migraine headache
US6333322B1 (en) 1996-03-13 2001-12-25 Eisai Co., Ltd. Nitrogen-containing tricyclic compounds and drugs containing the same
CA2278245A1 (en) 1997-01-21 1998-07-23 The American National Red Cross Intracellular and extracellular decontamination of whole blood and blood components by amphiphilic phenothiazin-5-ium dyes plus light
AU4322999A (en) 1998-06-01 1999-12-20 Advanced Research And Technology Institute, Inc. Methods and compositions for diagnosing tauopathies
FR2788436A1 (fr) 1999-01-14 2000-07-21 Pf Medicament Composition d'un derive de phenothiazine
AU2001229619A1 (en) 2000-01-21 2001-07-31 Pharmacia And Upjohn Company Transgenic mouse model of human neurodegenerative disease
GB0017060D0 (en) 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) * 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
AU2002345843A1 (en) 2001-06-22 2003-01-08 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US7410965B2 (en) 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
US6953974B2 (en) * 2003-08-26 2005-10-11 Texas Instruments Incorporated EEPROM device and method for providing lower programming voltage
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
WO2005054217A1 (en) 2003-11-28 2005-06-16 Photopharmica Limited Developments in biologically active methylene blue derivatives (2)
JP5186212B2 (ja) * 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
PT2322517T (pt) 2004-09-23 2019-07-30 Wista Lab Ltd Métodos de síntese química e purificação de compostos de diaminofenotiazínio incluindo cloreto de metiltionínio (mtc)
US20070116757A1 (en) * 2005-11-08 2007-05-24 Collegium Pharmaceutical, Inc. Methylene Blue Derivatives
PL2004155T3 (pl) 2006-03-29 2018-08-31 Wista Laboratories Ltd. Inhibitory agregacji białek
KR100983301B1 (ko) * 2006-03-29 2010-09-20 위스타 레보레이토리스 리미티드 ３,７―다이아미노―１０ｈ―페노티아진염 및 이의 용도
MY172157A (en) 2006-03-29 2019-11-15 Wista Lab Ltd Thioninium compounds and their use
AU2007274057B2 (en) 2006-07-11 2012-12-13 TauRx Therapeutics Management Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
PL2167095T3 (pl) 2007-06-19 2019-11-29 Wista Lab Ltd Związki fenotiazynowe do leczenia łagodnych zaburzeń poznawczych
EP2954932B1 (de) 2007-10-03 2018-09-19 WisTa Laboratories Ltd. Therapeutische verwendung von diaminophenothiazinen
JP5898701B2 (ja) 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
JP7317787B2 (ja) 2020-10-19 2023-07-31 トヨタ自動車株式会社 排ガス浄化装置

Also Published As

Publication number Publication date
CN104606199A (zh) 2015-05-13
PL2013191T6 (pl) 2019-07-31
JP2013121985A (ja) 2013-06-20
US7888350B2 (en) 2011-02-15
WO2007110627A3 (en) 2007-11-22
JP5814957B2 (ja) 2015-11-17
DK2013191T6 (en) 2019-04-23
MY143757A (en) 2011-07-15
EA200870384A1 (ru) 2009-04-28
DK2013191T3 (da) 2010-11-22
HRP20100614T1 (hr) 2010-12-31
ES2349322T3 (es) 2010-12-29
CN109384741A (zh) 2019-02-26
WO2007110627A2 (en) 2007-10-04
PT2013191E (pt) 2010-10-29
JP2009531403A (ja) 2009-09-03
EP2013191B3 (de) 2019-02-27
US20250325557A1 (en) 2025-10-23
JP2014055165A (ja) 2014-03-27
JP5520043B2 (ja) 2014-06-11
HK1199444A1 (en) 2015-07-03
KR100983301B1 (ko) 2010-09-20
HK1209417A1 (en) 2016-04-01
IL194516A0 (en) 2009-08-03
DE602007008550D1 (de) 2010-09-30
CN101460472B (zh) 2015-06-17
EP2013191B1 (de) 2010-08-18
US20240245700A1 (en) 2024-07-25
US12324810B2 (en) 2025-06-10
CN104119294B (zh) 2018-10-30
IL231890A (en) 2016-10-31
US11951110B2 (en) 2024-04-09
EP2013191A2 (de) 2009-01-14
HRP20100614T4 (hr) 2019-08-09
AU2007231124B2 (en) 2013-02-21
HK1210047A1 (en) 2016-04-15
CA2646163C (en) 2011-03-15
CN104529939B (zh) 2019-05-07
CN104119294A (zh) 2014-10-29
IL194516A (en) 2015-02-26
CN104529939A (zh) 2015-04-22
US20220152038A1 (en) 2022-05-19
AU2007231124A1 (en) 2007-10-04
CN101460472A (zh) 2009-06-17
EA014552B1 (ru) 2010-12-30
CA2646163F (en) 2007-10-04
ES2349322T7 (es) 2019-10-17
CN104606199B (zh) 2022-09-13
US11344558B2 (en) 2022-05-31
US20090054419A1 (en) 2009-02-26
PL2013191T3 (pl) 2011-02-28
CA2646163A1 (en) 2007-10-04
KR20080110879A (ko) 2008-12-19
HK1126480A1 (en) 2009-09-04
US20160051559A1 (en) 2016-02-25
IL231890A0 (en) 2014-05-28
CN109384741B (zh) 2023-01-06

Similar Documents

Publication Publication Date Title
ATE478058T3 (de) 3,7-diamino-10h-phenothiazinsalze und ihre verwendung
MY139446A (en) Novel quinoline derivatives
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
MX2010006182A (es) Derivados de isoxazolo-piridazina.
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
SG159380A1 (en) Heteroaryl compounds useful as inhibitors of gsk-3
GEP201706611B (en) Amido compounds and their use as pharmaceuticals
UA100132C2 (en) Isoxazolo-pyridine derivatives
SE0102300D0 (sv) Compounds
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
MXPA06002296A (es) Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.
PT1268418E (pt) Derivados da pirrolidina farmacologicamente activos com inibidores bax
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
NO20084516L (no) Terfenylderivater for behandling av alzheimers sykdom
TW200640900A (en) 1-(2h)-isoquinolone derivative
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
SG161217A1 (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
EA200801134A1 (ru) Замещенные бициклические пиримидоновые производные
EA200701035A1 (ru) Замещенные n-сульфониламинобензил-2-феноксиацетамидные соединения
TW200704633A (en) Process for the preparation of sulfonamide derivatives
TW200700390A (en) Metabolites for nk-1 antagonists for emesis
BRPI0517734A (pt) derivados de 1-[(6,7-alcoxiquinoxalinil substituìdo) aminocarbonil]-4- (hetero) arilpiperazina
ATE412416T1 (de) Indolin-2-one-pyridin-derivate, herstellung und therapeutische verwendung dafür

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2013191

Country of ref document: EP